Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase EARLY_PHASE1 4Phase NA 3Phase 1/2 2Phase 4 1Phase 2/3 1

Status

Recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Conditions

Polycystic Ovary Syndrome 4Hyperandrogenism 3Inflammation 1

Interventions

Magnetic Resonance Spectroscopy 61Cyclophosphamide 57pembrolizumab 39fludarabine 38Radiotherapy 30Nivolumab 30Biopsy 27Metformin 23Fluorodeoxyglucose F18 22Bevacizumab 22Specimen Handling 21Temozolomide 18Cisplatin 18Radiosurgery 17Carboplatin 16Fluorouracil 15Paclitaxel 14Dexamethasone 14Radiation 13Gemcitabine 13Etoposide 13Rituximab 12Positron Emission Tomography Computed Tomography 12Letrozole 12Irinotecan 12gallium 68 PSMA-11 11durvalumab 11atezolizumab 11X-Rays 11Surgical Procedures, Operative 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Interventional × Spironolactone × Clear all
NCT03068910 2025-08-05

CRM008

University of Virginia

Phase EARLY_PHASE1 Recruiting
32 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

NCT04723862 2025-08-05

CBS010

University of Virginia

Phase EARLY_PHASE1 Recruiting
32 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

NCT04075149 2023-10-27

CBS009

University of Virginia

Phase EARLY_PHASE1 Unknown
24 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

NCT02689843 2019-11-12

AntiPCO

Shiraz University of Medical Sciences

Phase EARLY_PHASE1 Completed
90 enrolled

Inflammation, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡